Bay Area-based Graphite Bio launched with $45 million in Series A financing and a goal to use gene editing to correct defective genes through high-efficiency site-specific integration of new genetic sequences.

Moderna Inc. and Vertex Pharmaceuticals Incorporated announced a new strategic research collaboration and licensing agreement aimed at the discovery and development of lipid nanoparticles and mRNAs for the delivery of gene-editing therapies for the treatment of cystic fibrosis (CF).

Frost & Sullivan IDs Five New Technologies to Power Research Across Preclinical Disease Models Published: July 16, 2020 BioSpace When the CEOs of young, innovative biotech companies discuss how their new technologies came to be, they almost inevitably mention a convergence of technologies that was pivotal in transforming an idea into a therapeutic, diagnostic, tool […]

Light-activated CRISPR technology edits genes more precisely and faster than the more standard chemical methods, and enables “super-fast” DNA repair, according to research from Johns Hopkins University School of Medicine.

Bristol-Myers Squibb is taking aim at harnessing CRISPR-based solutions to treat certain cancers with a $65 million collaboration with Montreal-based Repare Therapeutics.

Weeks after Mammoth Biosciences announced the company’s CRISPR-based diagnostics test for COVID-19 had a high degree of specificity even for asymptomatic patients, the Bay Area-based firm struck a deal with GlaxoSmithKline to accelerate development of the test in hopes of getting them in consumer hands as soon as possible.

Intellia Therapeutics is focused on implementing a full-spectrum genome editing approach, as the company has a pipeline spanning both in vivo and ex vivo therapies to address severe and life-threatening diseases.

Researchers at the University of Pennsylvania and Children’s National Hospital in Washington, D.C., utilized a hybrid approach that combined gene therapy with gene editing to treat a rare genetic disease in animal models.

Researchers with the Abramson Cancer Center of the University of Pennsylvania, led by Carl June, published results from the first U.S. Phase I trial of CRISPR-Cas9-edited T-cells in humans with advanced cancer.

CRISPR Therapeutics and Vertex Pharmaceuticals announced positive interim data from the first patients in the companies’ Phase I/II clinical trials of the CRISPR/Cas9 gene-editing therapy CTX001.